首页> 美国卫生研究院文献>BMC Cancer >Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

【2h】

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

机译：获得性抗拉帕替尼耐药性的发展可能使HER2阳性乳腺癌细胞对obatoclax和TRAIL诱导的细胞凋亡敏感

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundLapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapatinib in HER2-positive breast cancer cells.

机译：背景拉帕替尼在治疗曲妥珠单抗难治性HER2阳性乳腺癌中具有临床疗效。然而，由于对药物的获得性耐药，很大一部分患者发展为进行性疾病。凋亡细胞的诱导是拉帕替尼在HER2阳性乳腺癌细胞中的关键作用机制。

著录项

期刊名称 BMC Cancer
作者
Alex J Eustace; Neil T Conlon; Martina S J McDermott; Brigid C Browne; Patrick O’Leary; Frankie A Holmes; Virginia Espina; Lance A Liotta; Joyce O’Shaughnessy; Clair Gallagher; Lorraine O’Driscoll; Sweta Rani; Stephen F Madden; Neil A O’Brien; Charles Ginther; Dennis Slamon; Naomi Walsh; William M Gallagher; Radoslaw Zagozdzon; William R Watson; Norma O’Donovan; John Crown;
展开▼
作者单位

展开▼
年(卷),期 2018(18),-1
年度 2018
页码 965
总页数 14
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
ErbB2 MCL-1 AKT FOXO3a cFLIP;

机译：ErbB2;MCL-1;AKT;FOXO3a;cFLIP;

相似文献

外文文献
中文文献
专利

1. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL [J] . Alex J Eustace, Neil T Conlon, Martina S J McDermott, BMC Cancer . 2018,第1期

机译：获得抗Lapatinib的获得性抗性的发展可能会使Her2阳性乳腺癌细胞敏化Obatoclax和Trail的凋亡诱导
2. Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-kappaB suppression. [J] . Lin T, Ding Z, Li N, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第12期

机译：硒代-环糊精通过DR5诱导和NF-κB抑制作用使人类乳腺癌细胞对TRAIL诱导的细胞凋亡敏感。
3. Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells [J] . Hung Chao-Ming, Liu Liang-Chih, Ho Chi-Tang, Journal of Agricultural and Food Chemistry . 2017,第51期

机译：活体内通过诱导死亡受体，在抗性三重阴性乳腺癌细胞中诱导死亡受体和细胞存活蛋白的下调，增强了诱导的细胞凋亡
4. Proteomics Proteomics Reveals Overexpression of the Tyrosine Kinase AXL as a Novel Mechanism of Lapatinib Resistance in Breast Tumor Cells [C] . Roland S. Annan, Therese Collingwood, Francesca Zappacosta, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：蛋白质组学蛋白质组学显示酪氨酸激酶AXL的过表达作为乳腺肿瘤细胞中Lapatinib抗性的新机制
5. Role of Lapatinib and Retinoids In Overcoming Intrinsic Resistance to Hormonal Therapy In Breast Cancer [D] . Gilani, Rabia Afzal 2011

机译：拉帕替尼和类维生素A在克服乳腺癌激素治疗的内在抗性中的作用
6. Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells [O] . Min Ye, Wei Huang, Rui Liu, 2021

机译：HSP90抑制剂Ganetespib的协同活性用Lapatinib逆转HER2阳性乳腺癌细胞中的Lapatinib抗性
7. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. [O] . Elster Naomi, Cremona Mattia, Morgan Carys, 2015

机译：在对HER2靶向疗法曲妥珠单抗和拉帕替尼具有获得性耐药的HER2阳性乳腺癌模型中，PI3Kα/δ显性抑制剂BAY 80-6946的临床前评估。

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

摘要

著录项

相似文献

相关主题

期刊订阅